Who are Akero's investors?

Akero's investors include Atlas Venture, Foresite Capital, Frazier Life Sciences, General Atlantic, LifeSci Venture Partners, Scion Life Sciences, The Innovation Space, venBio Partners and 1 more.

Akero

Founded 2017 · 74 employees on LinkedIn · 9 known investors

Find your way into Akero

Paths you didn't know you had: your email and LinkedIn already hold routes to the Akero team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need. The company's lead candidate, efruxifermin, is in phase 3 clinical trials for liver disease treatment.

Biotech Healthtech Medical Devices

Investors · 9

Atlas Venturelisted by Atlas VentureCambridge · $500K – $1M

How we know: Atlas Venture's portfolio page · Not right? Tell us

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · Not right? Tell us

Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto

How we know: Frazier Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

General Atlanticlisted by General AtlanticNew York · $10M – $1B

How we know: generalatlantic.com · Not right? Tell us

LifeSci Venture Partnerslisted by LifeSci Venture PartnersNew York

How we know: LifeSci Venture Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Scion Life Scienceslisted by Scion Life SciencesNew York · $1K – $60M

How we know: Scion Life Sciences's portfolio page · Not right? Tell us

The Innovation Spacelisted by The Innovation SpaceWilmington · $200K

How we know: The Innovation Space's portfolio page · Not right? Tell us

venBio Partnerslisted by venBio PartnersSan Francisco

How we know: the VCSheet dataset · Not right? Tell us

Versant Ventureslisted by Versant VenturesSan Francisco · $250K – $5M

How we know: Versant Ventures's portfolio page · Not right? Tell us

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies working in the same space as Akero.

Frequently asked questions

What does Akero do?: Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need. The company's lead candidate, efruxifermin, is in phase 3 clinical trials for liver disease treatment.
Who are Akero's investors?: Akero's investors include Atlas Venture, Foresite Capital, Frazier Life Sciences, General Atlantic, LifeSci Venture Partners, Scion Life Sciences, The Innovation Space, venBio Partners and 1 more.